The Development and Assessment of a Unique Disulfidptosis-Associated lncRNA Profile for Immune Microenvironment Prediction and Personalized Therapy in Gastric Adenocarcinoma
<b>Background:</b> Long non-coding RNAs (lncRNAs) are crucial factors affecting the occurrence, progression, and prognosis of gastric carcinoma (GC). The accumulation of disulfide bonds to excessive levels in cells expressing high <i>SLC7A11</i> triggers disulfidptosis, which...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-05-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/13/5/1224 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849711276539772928 |
|---|---|
| author | Jiyue Zhu Xiang Zhu Tingting Su Huiqing Zhou Shouhua Wang Weibin Shi |
| author_facet | Jiyue Zhu Xiang Zhu Tingting Su Huiqing Zhou Shouhua Wang Weibin Shi |
| author_sort | Jiyue Zhu |
| collection | DOAJ |
| description | <b>Background:</b> Long non-coding RNAs (lncRNAs) are crucial factors affecting the occurrence, progression, and prognosis of gastric carcinoma (GC). The accumulation of disulfide bonds to excessive levels in cells expressing high <i>SLC7A11</i> triggers disulfidptosis, which functions as a regulated form of cellular death. Research has demonstrated that upregulated <i>SLC7A11</i> is common in human cancers, but the effect of disulfidptosis on GC remains unclear. Identifying lncRNAs associated with disulfidptosis (drlncRNAs) and establishing a prognostic risk profile holds considerable importance for advancing GC research and treatment. <b>Methods:</b> Clinical records and transcriptomic datasets from individuals with GC were acquired from The Cancer Genome Atlas (TCGA) repository. A three-drlncRNA risk model was built using three common regression analysis methods. Then we used receiver operating characteristic (ROC) curves, independent prognostic analysis, and additional statistical approaches to assess the precision of the model. This investigation additionally encompassed Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis, immune cell infiltration evaluation, and pharmacological sensitivity predictions. To further investigate immunotherapy response disparities between patient cohorts with elevated- and reduced-risk scores, analyses of tumor mutational burden (TMB), tumor immune dysfunction and exclusion (TIDE), and microsatellite instability (MSI) were implemented. <b>Results:</b> We constructed a unique model composed of three drlncRNAs (AC107021.2, AC016394.2, and AC129507.1). Its independent prognostic capability for GC patients was validated through both single-variable and multivariable Cox regression analyses. GO and KEGG pathway assessments revealed predominant enrichment within the elevated-risk cohort, particularly in pathways involving sulfur compound interactions, traditional Wnt signaling mechanisms, cell-substrate adherens junctions, and cAMP signaling cascades, among others. Tumor microenvironment (TME) evaluation demonstrated elevated ImmuneScores, StromalScores, and ESTIMATEScores within the high-risk patient population. Concurrently, this elevated-risk cohort exhibited enhanced immune cell infiltration patterns, whereas the reduced-risk group displayed superior expression of immune checkpoints (ICPs). Additional investigations revealed that patients categorized into the reduced-risk classification possessed greater tumor mutational burden, increased MSI-high proportions, and diminished tumor immune dysfunction and exclusion scores compared to their high-risk counterparts. Pharmacological sensitivity assessments confirmed the superior efficacy of several therapeutic agents, including gemcitabine and veliparib (ABT.888), in patients with lower risk classifications. <b>Conclusions:</b> Our established risk stratification system demonstrates independent prognostic predictive capacity while offering personalized clinical intervention guidance for individuals diagnosed with GC. |
| format | Article |
| id | doaj-art-7fd2145fa497430da0c7ed6be4bdab19 |
| institution | DOAJ |
| issn | 2227-9059 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj-art-7fd2145fa497430da0c7ed6be4bdab192025-08-20T03:14:39ZengMDPI AGBiomedicines2227-90592025-05-01135122410.3390/biomedicines13051224The Development and Assessment of a Unique Disulfidptosis-Associated lncRNA Profile for Immune Microenvironment Prediction and Personalized Therapy in Gastric AdenocarcinomaJiyue Zhu0Xiang Zhu1Tingting Su2Huiqing Zhou3Shouhua Wang4Weibin Shi5Department of General Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, ChinaDepartment of General Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, ChinaDepartment of General Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, ChinaDepartment of Gastroenterology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, ChinaDepartment of General Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, ChinaShanghai Key Laboratory of Biliary Tract Disease Research, Shanghai 200092, China<b>Background:</b> Long non-coding RNAs (lncRNAs) are crucial factors affecting the occurrence, progression, and prognosis of gastric carcinoma (GC). The accumulation of disulfide bonds to excessive levels in cells expressing high <i>SLC7A11</i> triggers disulfidptosis, which functions as a regulated form of cellular death. Research has demonstrated that upregulated <i>SLC7A11</i> is common in human cancers, but the effect of disulfidptosis on GC remains unclear. Identifying lncRNAs associated with disulfidptosis (drlncRNAs) and establishing a prognostic risk profile holds considerable importance for advancing GC research and treatment. <b>Methods:</b> Clinical records and transcriptomic datasets from individuals with GC were acquired from The Cancer Genome Atlas (TCGA) repository. A three-drlncRNA risk model was built using three common regression analysis methods. Then we used receiver operating characteristic (ROC) curves, independent prognostic analysis, and additional statistical approaches to assess the precision of the model. This investigation additionally encompassed Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis, immune cell infiltration evaluation, and pharmacological sensitivity predictions. To further investigate immunotherapy response disparities between patient cohorts with elevated- and reduced-risk scores, analyses of tumor mutational burden (TMB), tumor immune dysfunction and exclusion (TIDE), and microsatellite instability (MSI) were implemented. <b>Results:</b> We constructed a unique model composed of three drlncRNAs (AC107021.2, AC016394.2, and AC129507.1). Its independent prognostic capability for GC patients was validated through both single-variable and multivariable Cox regression analyses. GO and KEGG pathway assessments revealed predominant enrichment within the elevated-risk cohort, particularly in pathways involving sulfur compound interactions, traditional Wnt signaling mechanisms, cell-substrate adherens junctions, and cAMP signaling cascades, among others. Tumor microenvironment (TME) evaluation demonstrated elevated ImmuneScores, StromalScores, and ESTIMATEScores within the high-risk patient population. Concurrently, this elevated-risk cohort exhibited enhanced immune cell infiltration patterns, whereas the reduced-risk group displayed superior expression of immune checkpoints (ICPs). Additional investigations revealed that patients categorized into the reduced-risk classification possessed greater tumor mutational burden, increased MSI-high proportions, and diminished tumor immune dysfunction and exclusion scores compared to their high-risk counterparts. Pharmacological sensitivity assessments confirmed the superior efficacy of several therapeutic agents, including gemcitabine and veliparib (ABT.888), in patients with lower risk classifications. <b>Conclusions:</b> Our established risk stratification system demonstrates independent prognostic predictive capacity while offering personalized clinical intervention guidance for individuals diagnosed with GC.https://www.mdpi.com/2227-9059/13/5/1224gastric cancerdisulfidptosislncRNATCGAprognostic modelimmune status |
| spellingShingle | Jiyue Zhu Xiang Zhu Tingting Su Huiqing Zhou Shouhua Wang Weibin Shi The Development and Assessment of a Unique Disulfidptosis-Associated lncRNA Profile for Immune Microenvironment Prediction and Personalized Therapy in Gastric Adenocarcinoma Biomedicines gastric cancer disulfidptosis lncRNA TCGA prognostic model immune status |
| title | The Development and Assessment of a Unique Disulfidptosis-Associated lncRNA Profile for Immune Microenvironment Prediction and Personalized Therapy in Gastric Adenocarcinoma |
| title_full | The Development and Assessment of a Unique Disulfidptosis-Associated lncRNA Profile for Immune Microenvironment Prediction and Personalized Therapy in Gastric Adenocarcinoma |
| title_fullStr | The Development and Assessment of a Unique Disulfidptosis-Associated lncRNA Profile for Immune Microenvironment Prediction and Personalized Therapy in Gastric Adenocarcinoma |
| title_full_unstemmed | The Development and Assessment of a Unique Disulfidptosis-Associated lncRNA Profile for Immune Microenvironment Prediction and Personalized Therapy in Gastric Adenocarcinoma |
| title_short | The Development and Assessment of a Unique Disulfidptosis-Associated lncRNA Profile for Immune Microenvironment Prediction and Personalized Therapy in Gastric Adenocarcinoma |
| title_sort | development and assessment of a unique disulfidptosis associated lncrna profile for immune microenvironment prediction and personalized therapy in gastric adenocarcinoma |
| topic | gastric cancer disulfidptosis lncRNA TCGA prognostic model immune status |
| url | https://www.mdpi.com/2227-9059/13/5/1224 |
| work_keys_str_mv | AT jiyuezhu thedevelopmentandassessmentofauniquedisulfidptosisassociatedlncrnaprofileforimmunemicroenvironmentpredictionandpersonalizedtherapyingastricadenocarcinoma AT xiangzhu thedevelopmentandassessmentofauniquedisulfidptosisassociatedlncrnaprofileforimmunemicroenvironmentpredictionandpersonalizedtherapyingastricadenocarcinoma AT tingtingsu thedevelopmentandassessmentofauniquedisulfidptosisassociatedlncrnaprofileforimmunemicroenvironmentpredictionandpersonalizedtherapyingastricadenocarcinoma AT huiqingzhou thedevelopmentandassessmentofauniquedisulfidptosisassociatedlncrnaprofileforimmunemicroenvironmentpredictionandpersonalizedtherapyingastricadenocarcinoma AT shouhuawang thedevelopmentandassessmentofauniquedisulfidptosisassociatedlncrnaprofileforimmunemicroenvironmentpredictionandpersonalizedtherapyingastricadenocarcinoma AT weibinshi thedevelopmentandassessmentofauniquedisulfidptosisassociatedlncrnaprofileforimmunemicroenvironmentpredictionandpersonalizedtherapyingastricadenocarcinoma AT jiyuezhu developmentandassessmentofauniquedisulfidptosisassociatedlncrnaprofileforimmunemicroenvironmentpredictionandpersonalizedtherapyingastricadenocarcinoma AT xiangzhu developmentandassessmentofauniquedisulfidptosisassociatedlncrnaprofileforimmunemicroenvironmentpredictionandpersonalizedtherapyingastricadenocarcinoma AT tingtingsu developmentandassessmentofauniquedisulfidptosisassociatedlncrnaprofileforimmunemicroenvironmentpredictionandpersonalizedtherapyingastricadenocarcinoma AT huiqingzhou developmentandassessmentofauniquedisulfidptosisassociatedlncrnaprofileforimmunemicroenvironmentpredictionandpersonalizedtherapyingastricadenocarcinoma AT shouhuawang developmentandassessmentofauniquedisulfidptosisassociatedlncrnaprofileforimmunemicroenvironmentpredictionandpersonalizedtherapyingastricadenocarcinoma AT weibinshi developmentandassessmentofauniquedisulfidptosisassociatedlncrnaprofileforimmunemicroenvironmentpredictionandpersonalizedtherapyingastricadenocarcinoma |